
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc has demonstrated strong financial performance, with order entry for 2025 increasing approximately 17% year-over-year, driven by robust demand in both banking and retail segments, indicating a healthy growth trajectory. The banking segment reported product revenues of $381 million, reflecting a 20% year-over-year increase and total revenues of $798 million, which rose 16% quarter-over-quarter and 11% year-over-year, showcasing the company's solid revenue generation capabilities. Furthermore, the company has consistently generated positive free cash flow, with CQ4 free cash flow reaching $196 million—a 5.4% increase from the prior year—marking the first instance of positive free cash flow across all four quarters, which bodes well for future financial stability and growth.
Bears say
The financial outlook for Diebold Nixdorf Inc. appears negative due to anticipated declines in backlog and quarterly results, reflecting typical seasonality. Additionally, the company may face risks that could negatively impact profitability, such as tariff-related costs, supply chain disruptions, and lower-than-expected demand for service upgrades in its primary Banking segment. Liquidity issues, indicated by a low average daily trading volume, further exacerbate financial uncertainty, potentially limiting investor interest and share performance.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares